Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Identification of novel HIV-1-derived HLA-E-binding peptides
Hannoun Z. et al, (2018), Immunology Letters, 202, 65 - 72
Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1
Borthwick NJ. et al, (2018), PLOS ONE, 13, e0197299 - e0197299
HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
Capucci S. et al, (2017), PLOS ONE, 12, e0181886 - e0181886
Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
Moyo N. et al, (2017), PLOS ONE, 12, e0181382 - e0181382
Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines
Borthwick N. et al, (2017), PLOS ONE, 12, e0176418 - e0176418
A statistical approach to determining responses to individual peptides from pooled-peptide ELISpot data
Ström P. et al, (2016), Journal of Immunological Methods, 435, 43 - 49
Control of HIV-1 replication in vitro by vaccine-induced human CD8+ T cells through conserved subdominant Pol epitopes
Ahmed T. et al, (2016), Vaccine, 34, 1215 - 1224
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults
Mutua G. et al, (2016), Molecular Therapy - Methods & Clinical Development, 3, 16061 - 16061
Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells
Ternette N. et al, (2015), Journal of Virology, 89, 5760 - 5771
Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques
Borthwick NJ. et al, (2015), Immunity, Inflammation and Disease, 3, 82 - 93
PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi
Njuguna IN. et al, (2014), Vaccine, 32, 5801 - 5808
PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi
Njuguna IN. et al, (2014), Vaccine, 32, 5801 - 5808
Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: Mapping of CD8+ T Cell Epitopes
Borthwick NJ. et al, (2014), AIDS Research and Human Retroviruses, 30, A187 - A187
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
Borthwick N. et al, (2014), Molecular Therapy, 22, 464 - 475
A Phase I Randomized Clinical Trial of Candidate Human Immunodeficiency Virus type 1 Vaccine MVA.HIVA Administered to Gambian Infants
Afolabi MO. et al, (2013), PLoS ONE, 8, e78289 - e78289
Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
Borthwick NJ. et al, (2012), Retrovirology, 9
Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques
Rosario M. et al, (2012), AIDS, 26, 275 - 284
The biology of micrometastases from uveal melanoma
Borthwick NJ. et al, (2011), Journal of Clinical Pathology, 64, 666 - 671
Safety and Immunogenicity of Novel Recombinant BCG and Modified Vaccinia Virus Ankara Vaccines in Neonate Rhesus Macaques
Rosario M. et al, (2010), Journal of Virology, 84, 7815 - 7821
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques
Rosario M. et al, (2010), European Journal of Immunology, 40, 1973 - 1984